Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice

For a nationwide real-word data study on the application of predictive mutation testing of patients with colorectal cancer (CRC) for anti-epidermal growth factor receptor (EGFR) therapy stratification, pathology data were collected from the Dutch Pathology Registry from October 2017 until June 2019...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pathology 2022-10, Vol.75 (10), p.706-711
Hauptverfasser: Steeghs, Elisabeth M P, Vink, Geraldine R, Elferink, Marloes A G, Voorham, Quirinus J M, Gelderblom, Hans, Nagtegaal, Iris D, Grünberg, Katrien, Ligtenberg, Marjolijn J L, Drillenburg, P, Nijhuis, E W P, van de Vijver, M J, van Noesel, C J, Bloemena, E, Heideman, D A M, Radonic, T, Thunissen, E, Nederlof, P M, Meijer, G A, Monkhorst, K, Doornewaard, H, Dijk, M C R F van, Ruijter, E, Duthoi, K, Meijers, C, van de Brule, A J C, Nooijen, P T G A, Bot, F J, Hazalbag, H M, Clahsen, P, van Nederveen, F H, Westenend, P J, Jeuken, J W M, Ahsmann, E J M, Meulbroek, P, Timens, W, Schuuring, E, van Kempen, L C, Geuken, W, Bulkmans, N W J, Bellot, F E, Clarijs, R, Riemersma, S, van der Geize, R, Meijer, J, van Slooten, H J, Kibbelaar, R E, van der Logt, E M J, van Wezel, T, Morreau, H, Bovee, J V M G, Zur Hausen, A, Speel, E J M, de Bruin, P C, Huijsmans, C J, Dusseljee, S, Willems, R W, Prinsen, C F, Zomer, S, van Kemenade, F J, Dinjens, W N M, Geurts-Giele, W R R, van der Valk, H, Smits, A J J, Hoogduin, K J, Kliffen, M, den Bakker, M A, Stavast, J, van Diest, P J, de Leng, W W J, de Bruïne, A P, Hinrichs, J W J, Meischl, C, Gaal, J, Niemantsverdriet, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 711
container_issue 10
container_start_page 706
container_title Journal of clinical pathology
container_volume 75
creator Steeghs, Elisabeth M P
Vink, Geraldine R
Elferink, Marloes A G
Voorham, Quirinus J M
Gelderblom, Hans
Nagtegaal, Iris D
Grünberg, Katrien
Ligtenberg, Marjolijn J L
Drillenburg, P
Nijhuis, E W P
van de Vijver, M J
van Noesel, C J
Bloemena, E
Heideman, D A M
Radonic, T
Thunissen, E
Nederlof, P M
Meijer, G A
Monkhorst, K
Doornewaard, H
Dijk, M C R F van
Ruijter, E
Duthoi, K
Meijers, C
van de Brule, A J C
Nooijen, P T G A
Bot, F J
Hazalbag, H M
Clahsen, P
van Nederveen, F H
Westenend, P J
Jeuken, J W M
Ahsmann, E J M
Meulbroek, P
Timens, W
Schuuring, E
van Kempen, L C
Geuken, W
Bulkmans, N W J
Bellot, F E
Clarijs, R
Riemersma, S
van der Geize, R
Meijer, J
van Slooten, H J
Kibbelaar, R E
van der Logt, E M J
van Wezel, T
Morreau, H
Bovee, J V M G
Zur Hausen, A
Speel, E J M
de Bruin, P C
Huijsmans, C J
Dusseljee, S
Willems, R W
Prinsen, C F
Zomer, S
van Kemenade, F J
Dinjens, W N M
Geurts-Giele, W R R
van der Valk, H
Smits, A J J
Hoogduin, K J
Kliffen, M
den Bakker, M A
Stavast, J
van Diest, P J
de Leng, W W J
de Bruïne, A P
Hinrichs, J W J
Meischl, C
Gaal, J
Niemantsverdriet, M
description For a nationwide real-word data study on the application of predictive mutation testing of patients with colorectal cancer (CRC) for anti-epidermal growth factor receptor (EGFR) therapy stratification, pathology data were collected from the Dutch Pathology Registry from October 2017 until June 2019 (N=4060) and linked with the Netherlands Cancer Registry. Mutation testing rates increased from 24% at diagnosis of stage IV disease to 60% after 20–23 months of follow-up (p
doi_str_mv 10.1136/jclinpath-2021-207865
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9510427</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2584435207</sourcerecordid><originalsourceid>FETCH-LOGICAL-b429t-bcff725347fe124b119b5c440cfa998a873770e18f7e10da7740aee91bf711993</originalsourceid><addsrcrecordid>eNp9kU2P1SAYhYnRONfRn6AhceOmCpSWsjExk5nRZKKJ0TWh9K2XGwoV6Ezu3h8uvXe8fizc8JH3OYdDDkLPKXlNad2-2Rln_azztmKE0bKIrm0eoA3lglWc8vYh2pB1IgVvz9CTlHaE0FrQ-jE6q3krGiLJBv34qLMN_s4OgOFWu-VwxWHE05IP5ypr60KEAWufbXV5ffUZ5y1EPe9xAgfmILAelzAWfE74zuYtNmEVmawdNtobiCsyFKs9XpNbUwZz1EVt4Cl6NGqX4Nn9fo6-Xl1-uXhf3Xy6_nDx7qbqOZO56s04CtbUXIxAGe8plX1jOCdm1FJ2uhO1EARoNwqgZNBCcKIBJO1HUVhZn6O3R9956ScYTEkbtVNztJOOexW0VX9PvN2qb-FWyYYSzkQxeHVvEMP3BVJWk00GnNMewpIUazrO66aUUdCX_6C7sERfvqdY1wnJpDgkao6UiSGlCOMpDCVq7VmdelZrz-rYc9G9-PMnJ9WvYgtAj0A_7X6__H_Tn1GeucA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2887929799</pqid></control><display><type>article</type><title>Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice</title><source>PubMed Central</source><creator>Steeghs, Elisabeth M P ; Vink, Geraldine R ; Elferink, Marloes A G ; Voorham, Quirinus J M ; Gelderblom, Hans ; Nagtegaal, Iris D ; Grünberg, Katrien ; Ligtenberg, Marjolijn J L ; Drillenburg, P ; Nijhuis, E W P ; van de Vijver, M J ; van Noesel, C J ; Bloemena, E ; Heideman, D A M ; Radonic, T ; Thunissen, E ; Nederlof, P M ; Meijer, G A ; Monkhorst, K ; Doornewaard, H ; Dijk, M C R F van ; Ruijter, E ; Duthoi, K ; Meijers, C ; van de Brule, A J C ; Nooijen, P T G A ; Bot, F J ; Hazalbag, H M ; Clahsen, P ; van Nederveen, F H ; Westenend, P J ; Jeuken, J W M ; Ahsmann, E J M ; Meulbroek, P ; Timens, W ; Schuuring, E ; van Kempen, L C ; Geuken, W ; Bulkmans, N W J ; Bellot, F E ; Clarijs, R ; Riemersma, S ; van der Geize, R ; Meijer, J ; van Slooten, H J ; Kibbelaar, R E ; van der Logt, E M J ; van Wezel, T ; Morreau, H ; Bovee, J V M G ; Zur Hausen, A ; Speel, E J M ; de Bruin, P C ; Huijsmans, C J ; Dusseljee, S ; Willems, R W ; Prinsen, C F ; Zomer, S ; van Kemenade, F J ; Dinjens, W N M ; Geurts-Giele, W R R ; van der Valk, H ; Smits, A J J ; Hoogduin, K J ; Kliffen, M ; den Bakker, M A ; Stavast, J ; van Diest, P J ; de Leng, W W J ; de Bruïne, A P ; Hinrichs, J W J ; Meischl, C ; Gaal, J ; Niemantsverdriet, M</creator><creatorcontrib>Steeghs, Elisabeth M P ; Vink, Geraldine R ; Elferink, Marloes A G ; Voorham, Quirinus J M ; Gelderblom, Hans ; Nagtegaal, Iris D ; Grünberg, Katrien ; Ligtenberg, Marjolijn J L ; Drillenburg, P ; Nijhuis, E W P ; van de Vijver, M J ; van Noesel, C J ; Bloemena, E ; Heideman, D A M ; Radonic, T ; Thunissen, E ; Nederlof, P M ; Meijer, G A ; Monkhorst, K ; Doornewaard, H ; Dijk, M C R F van ; Ruijter, E ; Duthoi, K ; Meijers, C ; van de Brule, A J C ; Nooijen, P T G A ; Bot, F J ; Hazalbag, H M ; Clahsen, P ; van Nederveen, F H ; Westenend, P J ; Jeuken, J W M ; Ahsmann, E J M ; Meulbroek, P ; Timens, W ; Schuuring, E ; van Kempen, L C ; Geuken, W ; Bulkmans, N W J ; Bellot, F E ; Clarijs, R ; Riemersma, S ; van der Geize, R ; Meijer, J ; van Slooten, H J ; Kibbelaar, R E ; van der Logt, E M J ; van Wezel, T ; Morreau, H ; Bovee, J V M G ; Zur Hausen, A ; Speel, E J M ; de Bruin, P C ; Huijsmans, C J ; Dusseljee, S ; Willems, R W ; Prinsen, C F ; Zomer, S ; van Kemenade, F J ; Dinjens, W N M ; Geurts-Giele, W R R ; van der Valk, H ; Smits, A J J ; Hoogduin, K J ; Kliffen, M ; den Bakker, M A ; Stavast, J ; van Diest, P J ; de Leng, W W J ; de Bruïne, A P ; Hinrichs, J W J ; Meischl, C ; Gaal, J ; Niemantsverdriet, M ; PATH Consortium Members</creatorcontrib><description>For a nationwide real-word data study on the application of predictive mutation testing of patients with colorectal cancer (CRC) for anti-epidermal growth factor receptor (EGFR) therapy stratification, pathology data were collected from the Dutch Pathology Registry from October 2017 until June 2019 (N=4060) and linked with the Netherlands Cancer Registry. Mutation testing rates increased from 24% at diagnosis of stage IV disease to 60% after 20–23 months of follow-up (p&lt;0.001). Application of anti-EGFR therapy in KRAS/NRAS wild-type patients was mainly observed from the third treatment line onwards (65% vs 17% in first/second treatment line (p&lt;0.001)). The national average KRAS/NRAS/BRAF mutation rate was 63.9%, being similar for next-generation sequencing (NGS)-based approaches and single gene tests (64.4% vs 61.2%, p=ns). NGS-based approaches detected more additional potential biomarkers, for example, ERBB2 amplifications (p&lt;0.05). Therefore, single gene tests are suitable to stratify patients with mCRC for anti-EGFR therapy, but NGS is superior enabling upfront identification of therapy resistance or facilitate enrolment into clinical trials.</description><identifier>ISSN: 0021-9746</identifier><identifier>ISSN: 1472-4146</identifier><identifier>EISSN: 1472-4146</identifier><identifier>DOI: 10.1136/jclinpath-2021-207865</identifier><identifier>PMID: 34675090</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and Association of Clinical Pathologists</publisher><subject>Biomarkers ; Cancer therapies ; Clinical medicine ; Colorectal cancer ; colorectal neoplasms ; Data collection ; Datasets ; Departments ; diagnostic techniques and procedures ; Genes ; Metastasis ; molecular ; Mutation ; Pathology ; Patients ; Short Report ; Tumors</subject><ispartof>Journal of clinical pathology, 2022-10, Vol.75 (10), p.706-711</ispartof><rights>Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-b429t-bcff725347fe124b119b5c440cfa998a873770e18f7e10da7740aee91bf711993</cites><orcidid>0000-0003-1290-1474</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510427/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510427/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34675090$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Steeghs, Elisabeth M P</creatorcontrib><creatorcontrib>Vink, Geraldine R</creatorcontrib><creatorcontrib>Elferink, Marloes A G</creatorcontrib><creatorcontrib>Voorham, Quirinus J M</creatorcontrib><creatorcontrib>Gelderblom, Hans</creatorcontrib><creatorcontrib>Nagtegaal, Iris D</creatorcontrib><creatorcontrib>Grünberg, Katrien</creatorcontrib><creatorcontrib>Ligtenberg, Marjolijn J L</creatorcontrib><creatorcontrib>Drillenburg, P</creatorcontrib><creatorcontrib>Nijhuis, E W P</creatorcontrib><creatorcontrib>van de Vijver, M J</creatorcontrib><creatorcontrib>van Noesel, C J</creatorcontrib><creatorcontrib>Bloemena, E</creatorcontrib><creatorcontrib>Heideman, D A M</creatorcontrib><creatorcontrib>Radonic, T</creatorcontrib><creatorcontrib>Thunissen, E</creatorcontrib><creatorcontrib>Nederlof, P M</creatorcontrib><creatorcontrib>Meijer, G A</creatorcontrib><creatorcontrib>Monkhorst, K</creatorcontrib><creatorcontrib>Doornewaard, H</creatorcontrib><creatorcontrib>Dijk, M C R F van</creatorcontrib><creatorcontrib>Ruijter, E</creatorcontrib><creatorcontrib>Duthoi, K</creatorcontrib><creatorcontrib>Meijers, C</creatorcontrib><creatorcontrib>van de Brule, A J C</creatorcontrib><creatorcontrib>Nooijen, P T G A</creatorcontrib><creatorcontrib>Bot, F J</creatorcontrib><creatorcontrib>Hazalbag, H M</creatorcontrib><creatorcontrib>Clahsen, P</creatorcontrib><creatorcontrib>van Nederveen, F H</creatorcontrib><creatorcontrib>Westenend, P J</creatorcontrib><creatorcontrib>Jeuken, J W M</creatorcontrib><creatorcontrib>Ahsmann, E J M</creatorcontrib><creatorcontrib>Meulbroek, P</creatorcontrib><creatorcontrib>Timens, W</creatorcontrib><creatorcontrib>Schuuring, E</creatorcontrib><creatorcontrib>van Kempen, L C</creatorcontrib><creatorcontrib>Geuken, W</creatorcontrib><creatorcontrib>Bulkmans, N W J</creatorcontrib><creatorcontrib>Bellot, F E</creatorcontrib><creatorcontrib>Clarijs, R</creatorcontrib><creatorcontrib>Riemersma, S</creatorcontrib><creatorcontrib>van der Geize, R</creatorcontrib><creatorcontrib>Meijer, J</creatorcontrib><creatorcontrib>van Slooten, H J</creatorcontrib><creatorcontrib>Kibbelaar, R E</creatorcontrib><creatorcontrib>van der Logt, E M J</creatorcontrib><creatorcontrib>van Wezel, T</creatorcontrib><creatorcontrib>Morreau, H</creatorcontrib><creatorcontrib>Bovee, J V M G</creatorcontrib><creatorcontrib>Zur Hausen, A</creatorcontrib><creatorcontrib>Speel, E J M</creatorcontrib><creatorcontrib>de Bruin, P C</creatorcontrib><creatorcontrib>Huijsmans, C J</creatorcontrib><creatorcontrib>Dusseljee, S</creatorcontrib><creatorcontrib>Willems, R W</creatorcontrib><creatorcontrib>Prinsen, C F</creatorcontrib><creatorcontrib>Zomer, S</creatorcontrib><creatorcontrib>van Kemenade, F J</creatorcontrib><creatorcontrib>Dinjens, W N M</creatorcontrib><creatorcontrib>Geurts-Giele, W R R</creatorcontrib><creatorcontrib>van der Valk, H</creatorcontrib><creatorcontrib>Smits, A J J</creatorcontrib><creatorcontrib>Hoogduin, K J</creatorcontrib><creatorcontrib>Kliffen, M</creatorcontrib><creatorcontrib>den Bakker, M A</creatorcontrib><creatorcontrib>Stavast, J</creatorcontrib><creatorcontrib>van Diest, P J</creatorcontrib><creatorcontrib>de Leng, W W J</creatorcontrib><creatorcontrib>de Bruïne, A P</creatorcontrib><creatorcontrib>Hinrichs, J W J</creatorcontrib><creatorcontrib>Meischl, C</creatorcontrib><creatorcontrib>Gaal, J</creatorcontrib><creatorcontrib>Niemantsverdriet, M</creatorcontrib><creatorcontrib>PATH Consortium Members</creatorcontrib><title>Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice</title><title>Journal of clinical pathology</title><addtitle>J Clin Pathol</addtitle><addtitle>J Clin Pathol</addtitle><description>For a nationwide real-word data study on the application of predictive mutation testing of patients with colorectal cancer (CRC) for anti-epidermal growth factor receptor (EGFR) therapy stratification, pathology data were collected from the Dutch Pathology Registry from October 2017 until June 2019 (N=4060) and linked with the Netherlands Cancer Registry. Mutation testing rates increased from 24% at diagnosis of stage IV disease to 60% after 20–23 months of follow-up (p&lt;0.001). Application of anti-EGFR therapy in KRAS/NRAS wild-type patients was mainly observed from the third treatment line onwards (65% vs 17% in first/second treatment line (p&lt;0.001)). The national average KRAS/NRAS/BRAF mutation rate was 63.9%, being similar for next-generation sequencing (NGS)-based approaches and single gene tests (64.4% vs 61.2%, p=ns). NGS-based approaches detected more additional potential biomarkers, for example, ERBB2 amplifications (p&lt;0.05). Therefore, single gene tests are suitable to stratify patients with mCRC for anti-EGFR therapy, but NGS is superior enabling upfront identification of therapy resistance or facilitate enrolment into clinical trials.</description><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Clinical medicine</subject><subject>Colorectal cancer</subject><subject>colorectal neoplasms</subject><subject>Data collection</subject><subject>Datasets</subject><subject>Departments</subject><subject>diagnostic techniques and procedures</subject><subject>Genes</subject><subject>Metastasis</subject><subject>molecular</subject><subject>Mutation</subject><subject>Pathology</subject><subject>Patients</subject><subject>Short Report</subject><subject>Tumors</subject><issn>0021-9746</issn><issn>1472-4146</issn><issn>1472-4146</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU2P1SAYhYnRONfRn6AhceOmCpSWsjExk5nRZKKJ0TWh9K2XGwoV6Ezu3h8uvXe8fizc8JH3OYdDDkLPKXlNad2-2Rln_azztmKE0bKIrm0eoA3lglWc8vYh2pB1IgVvz9CTlHaE0FrQ-jE6q3krGiLJBv34qLMN_s4OgOFWu-VwxWHE05IP5ypr60KEAWufbXV5ffUZ5y1EPe9xAgfmILAelzAWfE74zuYtNmEVmawdNtobiCsyFKs9XpNbUwZz1EVt4Cl6NGqX4Nn9fo6-Xl1-uXhf3Xy6_nDx7qbqOZO56s04CtbUXIxAGe8plX1jOCdm1FJ2uhO1EARoNwqgZNBCcKIBJO1HUVhZn6O3R9956ScYTEkbtVNztJOOexW0VX9PvN2qb-FWyYYSzkQxeHVvEMP3BVJWk00GnNMewpIUazrO66aUUdCX_6C7sERfvqdY1wnJpDgkao6UiSGlCOMpDCVq7VmdelZrz-rYc9G9-PMnJ9WvYgtAj0A_7X6__H_Tn1GeucA</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Steeghs, Elisabeth M P</creator><creator>Vink, Geraldine R</creator><creator>Elferink, Marloes A G</creator><creator>Voorham, Quirinus J M</creator><creator>Gelderblom, Hans</creator><creator>Nagtegaal, Iris D</creator><creator>Grünberg, Katrien</creator><creator>Ligtenberg, Marjolijn J L</creator><creator>Drillenburg, P</creator><creator>Nijhuis, E W P</creator><creator>van de Vijver, M J</creator><creator>van Noesel, C J</creator><creator>Bloemena, E</creator><creator>Heideman, D A M</creator><creator>Radonic, T</creator><creator>Thunissen, E</creator><creator>Nederlof, P M</creator><creator>Meijer, G A</creator><creator>Monkhorst, K</creator><creator>Doornewaard, H</creator><creator>Dijk, M C R F van</creator><creator>Ruijter, E</creator><creator>Duthoi, K</creator><creator>Meijers, C</creator><creator>van de Brule, A J C</creator><creator>Nooijen, P T G A</creator><creator>Bot, F J</creator><creator>Hazalbag, H M</creator><creator>Clahsen, P</creator><creator>van Nederveen, F H</creator><creator>Westenend, P J</creator><creator>Jeuken, J W M</creator><creator>Ahsmann, E J M</creator><creator>Meulbroek, P</creator><creator>Timens, W</creator><creator>Schuuring, E</creator><creator>van Kempen, L C</creator><creator>Geuken, W</creator><creator>Bulkmans, N W J</creator><creator>Bellot, F E</creator><creator>Clarijs, R</creator><creator>Riemersma, S</creator><creator>van der Geize, R</creator><creator>Meijer, J</creator><creator>van Slooten, H J</creator><creator>Kibbelaar, R E</creator><creator>van der Logt, E M J</creator><creator>van Wezel, T</creator><creator>Morreau, H</creator><creator>Bovee, J V M G</creator><creator>Zur Hausen, A</creator><creator>Speel, E J M</creator><creator>de Bruin, P C</creator><creator>Huijsmans, C J</creator><creator>Dusseljee, S</creator><creator>Willems, R W</creator><creator>Prinsen, C F</creator><creator>Zomer, S</creator><creator>van Kemenade, F J</creator><creator>Dinjens, W N M</creator><creator>Geurts-Giele, W R R</creator><creator>van der Valk, H</creator><creator>Smits, A J J</creator><creator>Hoogduin, K J</creator><creator>Kliffen, M</creator><creator>den Bakker, M A</creator><creator>Stavast, J</creator><creator>van Diest, P J</creator><creator>de Leng, W W J</creator><creator>de Bruïne, A P</creator><creator>Hinrichs, J W J</creator><creator>Meischl, C</creator><creator>Gaal, J</creator><creator>Niemantsverdriet, M</creator><general>BMJ Publishing Group Ltd and Association of Clinical Pathologists</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1290-1474</orcidid></search><sort><creationdate>20221001</creationdate><title>Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice</title><author>Steeghs, Elisabeth M P ; Vink, Geraldine R ; Elferink, Marloes A G ; Voorham, Quirinus J M ; Gelderblom, Hans ; Nagtegaal, Iris D ; Grünberg, Katrien ; Ligtenberg, Marjolijn J L ; Drillenburg, P ; Nijhuis, E W P ; van de Vijver, M J ; van Noesel, C J ; Bloemena, E ; Heideman, D A M ; Radonic, T ; Thunissen, E ; Nederlof, P M ; Meijer, G A ; Monkhorst, K ; Doornewaard, H ; Dijk, M C R F van ; Ruijter, E ; Duthoi, K ; Meijers, C ; van de Brule, A J C ; Nooijen, P T G A ; Bot, F J ; Hazalbag, H M ; Clahsen, P ; van Nederveen, F H ; Westenend, P J ; Jeuken, J W M ; Ahsmann, E J M ; Meulbroek, P ; Timens, W ; Schuuring, E ; van Kempen, L C ; Geuken, W ; Bulkmans, N W J ; Bellot, F E ; Clarijs, R ; Riemersma, S ; van der Geize, R ; Meijer, J ; van Slooten, H J ; Kibbelaar, R E ; van der Logt, E M J ; van Wezel, T ; Morreau, H ; Bovee, J V M G ; Zur Hausen, A ; Speel, E J M ; de Bruin, P C ; Huijsmans, C J ; Dusseljee, S ; Willems, R W ; Prinsen, C F ; Zomer, S ; van Kemenade, F J ; Dinjens, W N M ; Geurts-Giele, W R R ; van der Valk, H ; Smits, A J J ; Hoogduin, K J ; Kliffen, M ; den Bakker, M A ; Stavast, J ; van Diest, P J ; de Leng, W W J ; de Bruïne, A P ; Hinrichs, J W J ; Meischl, C ; Gaal, J ; Niemantsverdriet, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b429t-bcff725347fe124b119b5c440cfa998a873770e18f7e10da7740aee91bf711993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Clinical medicine</topic><topic>Colorectal cancer</topic><topic>colorectal neoplasms</topic><topic>Data collection</topic><topic>Datasets</topic><topic>Departments</topic><topic>diagnostic techniques and procedures</topic><topic>Genes</topic><topic>Metastasis</topic><topic>molecular</topic><topic>Mutation</topic><topic>Pathology</topic><topic>Patients</topic><topic>Short Report</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Steeghs, Elisabeth M P</creatorcontrib><creatorcontrib>Vink, Geraldine R</creatorcontrib><creatorcontrib>Elferink, Marloes A G</creatorcontrib><creatorcontrib>Voorham, Quirinus J M</creatorcontrib><creatorcontrib>Gelderblom, Hans</creatorcontrib><creatorcontrib>Nagtegaal, Iris D</creatorcontrib><creatorcontrib>Grünberg, Katrien</creatorcontrib><creatorcontrib>Ligtenberg, Marjolijn J L</creatorcontrib><creatorcontrib>Drillenburg, P</creatorcontrib><creatorcontrib>Nijhuis, E W P</creatorcontrib><creatorcontrib>van de Vijver, M J</creatorcontrib><creatorcontrib>van Noesel, C J</creatorcontrib><creatorcontrib>Bloemena, E</creatorcontrib><creatorcontrib>Heideman, D A M</creatorcontrib><creatorcontrib>Radonic, T</creatorcontrib><creatorcontrib>Thunissen, E</creatorcontrib><creatorcontrib>Nederlof, P M</creatorcontrib><creatorcontrib>Meijer, G A</creatorcontrib><creatorcontrib>Monkhorst, K</creatorcontrib><creatorcontrib>Doornewaard, H</creatorcontrib><creatorcontrib>Dijk, M C R F van</creatorcontrib><creatorcontrib>Ruijter, E</creatorcontrib><creatorcontrib>Duthoi, K</creatorcontrib><creatorcontrib>Meijers, C</creatorcontrib><creatorcontrib>van de Brule, A J C</creatorcontrib><creatorcontrib>Nooijen, P T G A</creatorcontrib><creatorcontrib>Bot, F J</creatorcontrib><creatorcontrib>Hazalbag, H M</creatorcontrib><creatorcontrib>Clahsen, P</creatorcontrib><creatorcontrib>van Nederveen, F H</creatorcontrib><creatorcontrib>Westenend, P J</creatorcontrib><creatorcontrib>Jeuken, J W M</creatorcontrib><creatorcontrib>Ahsmann, E J M</creatorcontrib><creatorcontrib>Meulbroek, P</creatorcontrib><creatorcontrib>Timens, W</creatorcontrib><creatorcontrib>Schuuring, E</creatorcontrib><creatorcontrib>van Kempen, L C</creatorcontrib><creatorcontrib>Geuken, W</creatorcontrib><creatorcontrib>Bulkmans, N W J</creatorcontrib><creatorcontrib>Bellot, F E</creatorcontrib><creatorcontrib>Clarijs, R</creatorcontrib><creatorcontrib>Riemersma, S</creatorcontrib><creatorcontrib>van der Geize, R</creatorcontrib><creatorcontrib>Meijer, J</creatorcontrib><creatorcontrib>van Slooten, H J</creatorcontrib><creatorcontrib>Kibbelaar, R E</creatorcontrib><creatorcontrib>van der Logt, E M J</creatorcontrib><creatorcontrib>van Wezel, T</creatorcontrib><creatorcontrib>Morreau, H</creatorcontrib><creatorcontrib>Bovee, J V M G</creatorcontrib><creatorcontrib>Zur Hausen, A</creatorcontrib><creatorcontrib>Speel, E J M</creatorcontrib><creatorcontrib>de Bruin, P C</creatorcontrib><creatorcontrib>Huijsmans, C J</creatorcontrib><creatorcontrib>Dusseljee, S</creatorcontrib><creatorcontrib>Willems, R W</creatorcontrib><creatorcontrib>Prinsen, C F</creatorcontrib><creatorcontrib>Zomer, S</creatorcontrib><creatorcontrib>van Kemenade, F J</creatorcontrib><creatorcontrib>Dinjens, W N M</creatorcontrib><creatorcontrib>Geurts-Giele, W R R</creatorcontrib><creatorcontrib>van der Valk, H</creatorcontrib><creatorcontrib>Smits, A J J</creatorcontrib><creatorcontrib>Hoogduin, K J</creatorcontrib><creatorcontrib>Kliffen, M</creatorcontrib><creatorcontrib>den Bakker, M A</creatorcontrib><creatorcontrib>Stavast, J</creatorcontrib><creatorcontrib>van Diest, P J</creatorcontrib><creatorcontrib>de Leng, W W J</creatorcontrib><creatorcontrib>de Bruïne, A P</creatorcontrib><creatorcontrib>Hinrichs, J W J</creatorcontrib><creatorcontrib>Meischl, C</creatorcontrib><creatorcontrib>Gaal, J</creatorcontrib><creatorcontrib>Niemantsverdriet, M</creatorcontrib><creatorcontrib>PATH Consortium Members</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Steeghs, Elisabeth M P</au><au>Vink, Geraldine R</au><au>Elferink, Marloes A G</au><au>Voorham, Quirinus J M</au><au>Gelderblom, Hans</au><au>Nagtegaal, Iris D</au><au>Grünberg, Katrien</au><au>Ligtenberg, Marjolijn J L</au><au>Drillenburg, P</au><au>Nijhuis, E W P</au><au>van de Vijver, M J</au><au>van Noesel, C J</au><au>Bloemena, E</au><au>Heideman, D A M</au><au>Radonic, T</au><au>Thunissen, E</au><au>Nederlof, P M</au><au>Meijer, G A</au><au>Monkhorst, K</au><au>Doornewaard, H</au><au>Dijk, M C R F van</au><au>Ruijter, E</au><au>Duthoi, K</au><au>Meijers, C</au><au>van de Brule, A J C</au><au>Nooijen, P T G A</au><au>Bot, F J</au><au>Hazalbag, H M</au><au>Clahsen, P</au><au>van Nederveen, F H</au><au>Westenend, P J</au><au>Jeuken, J W M</au><au>Ahsmann, E J M</au><au>Meulbroek, P</au><au>Timens, W</au><au>Schuuring, E</au><au>van Kempen, L C</au><au>Geuken, W</au><au>Bulkmans, N W J</au><au>Bellot, F E</au><au>Clarijs, R</au><au>Riemersma, S</au><au>van der Geize, R</au><au>Meijer, J</au><au>van Slooten, H J</au><au>Kibbelaar, R E</au><au>van der Logt, E M J</au><au>van Wezel, T</au><au>Morreau, H</au><au>Bovee, J V M G</au><au>Zur Hausen, A</au><au>Speel, E J M</au><au>de Bruin, P C</au><au>Huijsmans, C J</au><au>Dusseljee, S</au><au>Willems, R W</au><au>Prinsen, C F</au><au>Zomer, S</au><au>van Kemenade, F J</au><au>Dinjens, W N M</au><au>Geurts-Giele, W R R</au><au>van der Valk, H</au><au>Smits, A J J</au><au>Hoogduin, K J</au><au>Kliffen, M</au><au>den Bakker, M A</au><au>Stavast, J</au><au>van Diest, P J</au><au>de Leng, W W J</au><au>de Bruïne, A P</au><au>Hinrichs, J W J</au><au>Meischl, C</au><au>Gaal, J</au><au>Niemantsverdriet, M</au><aucorp>PATH Consortium Members</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice</atitle><jtitle>Journal of clinical pathology</jtitle><stitle>J Clin Pathol</stitle><addtitle>J Clin Pathol</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>75</volume><issue>10</issue><spage>706</spage><epage>711</epage><pages>706-711</pages><issn>0021-9746</issn><issn>1472-4146</issn><eissn>1472-4146</eissn><abstract>For a nationwide real-word data study on the application of predictive mutation testing of patients with colorectal cancer (CRC) for anti-epidermal growth factor receptor (EGFR) therapy stratification, pathology data were collected from the Dutch Pathology Registry from October 2017 until June 2019 (N=4060) and linked with the Netherlands Cancer Registry. Mutation testing rates increased from 24% at diagnosis of stage IV disease to 60% after 20–23 months of follow-up (p&lt;0.001). Application of anti-EGFR therapy in KRAS/NRAS wild-type patients was mainly observed from the third treatment line onwards (65% vs 17% in first/second treatment line (p&lt;0.001)). The national average KRAS/NRAS/BRAF mutation rate was 63.9%, being similar for next-generation sequencing (NGS)-based approaches and single gene tests (64.4% vs 61.2%, p=ns). NGS-based approaches detected more additional potential biomarkers, for example, ERBB2 amplifications (p&lt;0.05). Therefore, single gene tests are suitable to stratify patients with mCRC for anti-EGFR therapy, but NGS is superior enabling upfront identification of therapy resistance or facilitate enrolment into clinical trials.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and Association of Clinical Pathologists</pub><pmid>34675090</pmid><doi>10.1136/jclinpath-2021-207865</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1290-1474</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9746
ispartof Journal of clinical pathology, 2022-10, Vol.75 (10), p.706-711
issn 0021-9746
1472-4146
1472-4146
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9510427
source PubMed Central
subjects Biomarkers
Cancer therapies
Clinical medicine
Colorectal cancer
colorectal neoplasms
Data collection
Datasets
Departments
diagnostic techniques and procedures
Genes
Metastasis
molecular
Mutation
Pathology
Patients
Short Report
Tumors
title Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-17T15%3A05%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nationwide%20evaluation%20of%20mutation-tailored%20anti-EGFR%20therapy%20selection%20in%20patients%20with%20colorectal%20cancer%20in%20daily%20clinical%20practice&rft.jtitle=Journal%20of%20clinical%20pathology&rft.au=Steeghs,%20Elisabeth%20M%20P&rft.aucorp=PATH%20Consortium%20Members&rft.date=2022-10-01&rft.volume=75&rft.issue=10&rft.spage=706&rft.epage=711&rft.pages=706-711&rft.issn=0021-9746&rft.eissn=1472-4146&rft_id=info:doi/10.1136/jclinpath-2021-207865&rft_dat=%3Cproquest_pubme%3E2584435207%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2887929799&rft_id=info:pmid/34675090&rfr_iscdi=true